Octavio Espinoza

Chief Financial Officer

Octavio Espinoza (Chief Financial Officer) filed 4 Form 4 reports in the trailing twelve months (0 purchases, 4 sales), most often in Ligand Pharmaceuticals Incorporated (LGND). The largest single filing was $9.2M of LGND (31,641 sh × $292.06, as filed), executed Aug 12.

Add to watchlist

Return, ttmiAverage return per filing, trailing twelve months

–

no purchases on file

Delay-adjustediThe same average, entered at disclosure dates

–

returns measure stock purchases only

Filings, ttm

0 buys · 4 sells

Median delay

–

execution → disclosure

Volume, ttmiDollar value disclosed in the trailing twelve months

$13.0M

shares × price, as filed

Last traded

Aug 12

Filed Aug 14

Median ADV $104.4M across their filed names

Open performance→

Volume by month

Buys $104K Sells $13.8M

Shares × price, as filed · by filing month · past 24 months

Sectors filed on

Healthcare 4 filings

Sector per market data · by filing · past 12 months

Most traded names

LGND

Ligand Pharmaceuticals Incorporated LGND · 1 buy · 6 sells 7 filings

Recent filings

LGNDSALE Ligand Pharmaceuticals Incorporated View filing → $9.2M
31,641 sh × $292.06
Exec Aug 12
Filed Aug 14 · 5:05 PM ET LGNDSALE Ligand Pharmaceuticals Incorporated View filing → $688K
3,057 sh × $225.00
Exec Mar 11
Filed Mar 13 · 5:30 PM ET LGNDSALE Ligand Pharmaceuticals Incorporated View filing → $2.8M
13,370 sh across 10 lots
Exec Mar 4
Filed Mar 6 · 5:30 PM ET LGNDSALE Ligand Pharmaceuticals Incorporated View filing → $340K
1,804 sh × $188.31
Exec Dec 12 2025
Filed Dec 16 2025 · 5:30 PM ET LGNDPURCHASE Ligand Pharmaceuticals Incorporated View filing → $104K
1,000 sh × $103.89
Exec May 9 2025
Filed May 13 2025 · 5:30 PM ET LGNDSALE Ligand Pharmaceuticals Incorporated View filing → $575K
5,000 sh × $115.03
Exec Mar 4 2025
Filed Mar 6 2025 · 5:30 PM ET LGNDSALE Ligand Pharmaceuticals Incorporated View filing → $245K
2,104 sh × $116.37
Exec Dec 23 2024
Filed Dec 26 2024 · 5:30 PM ET